Matinas BioPharma Holdings (MTNB) Short term Debt (2015)
Matinas BioPharma Holdings (MTNB) posted quarterly Short term Debt of $843674.0 for Q2 2015, little changed quarter-over-quarter from $843674.0 in Q1 2015.
Matinas BioPharma Holdings (MTNB) Short term Debt (2015) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Short term Debt for 1 consecutive years, with $843674.0 the latest figure, recorded in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.24 Mn | 430,519.83 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 843,674.00 |
| Mar 31, 2015 | 843,674.00 |